Leonteq Securities AG’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.05M Buy
22,000
+20,000
+1,000% +$859K 0.04% 257
2026
Q1
$73.5K Hold
2,000
﹤0.01% 791
2025
Q4
$102K Hold
2,000
﹤0.01% 802
2025
Q3
$111K Hold
2,000
﹤0.01% 721
2025
Q2
$138K Buy
2,000
+800
+67% +$54.4K 0.01% 648
2025
Q1
$83.3K Buy
+1,200
New +$99.1K ﹤0.01% 742

Other funds holding NVO

Leonteq Securities AG's NVO Position: Q2 2026 in Review

Leonteq Securities AG reduced its Novo Nordisk (NVO) stake by 81% in Q2 2026, selling an estimated $5.35M and leaving 28,796 shares worth $1.38M. The position accounts for 0.05% of the portfolio, ranked #223.

Leonteq Securities AG first reported a position in NVO in Q4 2020 and has held it in 21 quarters since. The position peaked at $22.1M in Q2 2025. 478 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Leonteq Securities AG held 28,796 shares of Novo Nordisk worth $1.38M as of Q2 2026.
  • Leonteq Securities AG sold 124,447 Novo Nordisk shares in Q2 2026, an estimated $5.35M.
  • Novo Nordisk made up 0.05% of Leonteq Securities AG's portfolio in Q2 2026, its #223 holding.
  • Leonteq Securities AG first reported a position in Novo Nordisk in Q4 2020 and has held it in 21 quarters since.
  • Leonteq Securities AG's Novo Nordisk position peaked at $22.1M in Q2 2025.
  • 478 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.